Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Launched by GYNECOLOGIC ONCOLOGY GROUP · Oct 22, 2009

Keywords

ClinConnect Summary

This clinical trial is studying tumor tissue samples from women who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. The goal is to understand how certain immune cells, called tumor infiltrating T cells, might help predict how well patients will respond to different treatments. By examining these tissue samples in the laboratory, researchers hope to gain valuable insights that could improve future care for women with this type of cancer.

To be eligible for this study, participants must have a confirmed diagnosis of stage III or IV ovarian epithelial cancer and have been part of specific chemotherapy trials. They also need to have preserved tissue samples from their surgery. If you or someone you know fits this description, participating in the study may involve providing some medical information and tissue samples, which could lead to advancements in understanding and treating ovarian cancer. It’s important to note that the study is currently recruiting participants and aims to gather as much data as possible to help improve treatment outcomes for future patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of stage III or IV ovarian epithelial cancer and enrolled on Gynecologic Oncology Group (GOG)-0136 and a GOG front-line platinum/taxol chemotherapy trial (GOG-0114, GOG-132, GOG-0158, or GOG-0162)
• * Must have fixed and paraffin-embedded tissue from primary surgery available from 1 of the following sources:
• • Patients enrolled on GOG-0136 and a GOG front-line platinum/taxol chemotherapy trial(GOG-0114, GOG-0132, GOG-0158, and GOG-0162)
• • Patients who have had either optimal or suboptimal cytoreductive surgery
• • Patients for whom adequate demographic data, including major prognostic factors and follow-up information, were collected
• • Evaluable patients must have had measurable or nonmeasurable disease
• • Demographic and follow-up data available